Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 8/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004776 | 0.90 | HTR1A (0.49) | BCHEHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL5253085 | 0.87 | MAPT (0.50) | HTR1AADRA1DADRA1AADRA1BMAOB | |
| SCHEMBL7834430 | 0.84 | HTR1A (0.51) | HTR1AADRA1DADRA1AADRA1BL3MBTL1 | |
| SCHEMBL21300617 | 0.83 | BCHE (0.67) | BCHEHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL8480468 | 0.83 | MAPT (0.61) | HTR1AADRA1DADRA1AADRA1BMAOB | |
| SCHEMBL7835236 | 0.83 | SMN1; SMN2 (0.46) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL18623128 | 0.80 | HTR1A (0.68) | BCHEHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL339374 | 0.79 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BMAOB | |
| SCHEMBL182637 | 0.79 | HTR1A (0.53) | BCHEHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL4198960 | 0.79 | MAPT (0.44) | HTR1AADRA1DADRA1AADRA1BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101402622-A | Synthesis and uses of 4,6,4'-trihydroxy-3',5'-dimethoxy aurone and its derivative | UNIV NANKAI (CN) | 2009-04-08 | — | — | CN | claimed |
| CN-1178789-A | Xanthene and arcridine derivative and its use | HOFFMANN LA ROCHE (CH) | 1998-04-15 | — | — | CN | claimed |
| EP-0823426-A1 | Xanthene and acridine derivatives and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-11 | — | — | EP | claimed |
| CN-111253336-B | Compounds for the treatment of cancer | GTX公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-106794174-B | Compounds for the treatment of cancer | GTX公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-111253336-A | Compounds for the treatment of cancer | GTX公司 | 2020-06-09 | — | — | CN | disclosed |
| CN-106794174-A | Compounds for the treatment of cancer | GTX公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20150073158-A1 | METHOD FOR PREPARING FUROFURAN LIGNAN COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2015-03-12 | — | — | US | disclosed |
| CN-101402622-B | Synthesis and uses of 4,6,4'-trihydroxy-3',5'-dimethoxy aurone and its derivative | UNIV NANKAI | 2012-09-19 | — | — | CN | disclosed |
| CN-101402622-B | Synthesis and uses of 4,6,4'-trihydroxy-3',5'-dimethoxy aurone and its derivative | UNIV NANKAI | 2012-09-19 | — | — | CN | disclosed |
| CN-101402622-A | Synthesis and uses of 4,6,4'-trihydroxy-3',5'-dimethoxy aurone and its derivative | UNIV NANKAI (CN) | 2009-04-08 | — | — | CN | disclosed |
| EP-0714898-B1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-1081149-A1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-6162918-A | Xanthene and acridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5969139-A | INHIBITORS OF HERPES SIMPLEX VIRUS THYMIDINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0823426-A1 | Xanthene and acridine derivatives and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-11 | — | — | EP | disclosed |
| US-5707997-A | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0714898-A1 | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-06-05 | — | — | EP | disclosed |
| US-5095020-A | Antitumor agents | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1992-03-10 | — | — | US | disclosed |
| EP-0357122-A2 | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073158-A1 | METHOD FOR PREPARING FUROFURAN LIGNAN COMPOUND | CYP4F2, UGT1A7, UGT1A3 | BCHE 1656/4885HTR1A 2642/4885ADRA1D 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.